Emergent BioSolutions Inc. (EBS)

In the past six months, Emergent BioSolutions reported its Third Quarter 2025 financial results, exceeding analysts' expectations. The company received FDA approval for drug product manufacturing of raxibacumab at its Winnipeg site. Emergent BioSolutions announced its presentation at the 44th Annual J.P. Morgan Healthcare Conference. The company received a delivery order to supply BioThrax® to the U.S. Department of War and announced an agreement to support the continuation of the Africa CDC-led MpOx Study in Africa. Emergent BioSolutions announced a voluntary prepayment of $100 million under its outstanding term loan principal. The FDA approved a supplemental New Drug Application for NARCAN® Nasal Spray to be packaged in a new carrying case. The stock price fell due to news that the New York Attorney General sued the former CEO for insider trading tied to COVID vaccine contamination. Emergent announced a resolution with the Office of the Attorney General of the State of New York regarding an investigation into legacy claims related to an executive trading plan from November 2020.

Information regarding the specific demand seasonality for Emergent BioSolutions' products and services is not readily available.

Emergent BioSolutions, Inc. is a life sciences company focused on preparedness and response solutions for public health threats, operating in the Healthcare sector, specifically in the Drug Manufacturers—Specialty & Generic industry. The company's portfolio includes commercial products like NARCAN® Nasal Spray, medical countermeasures (MCM products) such as Anthrax MCM products, Smallpox MCM products, Vaxchora® vaccine for cholera prevention, Vivotif® vaccine for typhoid fever, Botulism Antitoxin Heptavalent for botulism treatment, Ebanga® for Ebola, and Trobigard®. They also provide contract development and manufacturing services.

Emergent BioSolutions is headquartered in Gaithersburg, Maryland, United States. The company has research, development, and manufacturing facilities across North America, Europe, and Asia, with primary U.S. manufacturing sites in Maryland and Michigan. They serve government health agencies, commercial customers, and international markets through collaborations and supply agreements.

Emergent BioSolutions' brand reputation in the past year has been significantly affected by legal and regulatory matters. The New York Attorney General filed a lawsuit against the company's former CEO for alleged insider trading related to COVID vaccine contamination. Emergent BioSolutions announced a resolution with the Office of the Attorney General of the State of New York concerning an investigation into legacy claims regarding an executive trading plan approved in November 2020. These events likely contributed to a negative perception, as indicated by a significant drop in stock price.

As of February 5, 2026, Emergent BioSolutions Inc. has 297 institutional owners and shareholders holding a total of 45,942,880 shares. Institutions collectively hold 72.03% of the shares outstanding, while individuals/insiders hold 2.89%. Major institutional owners include BlackRock, Inc., Oak Hill Advisors Lp, Vanguard Group Inc, State Street Corp, American Century Companies Inc, Dimensional Fund Advisors Lp, and Geode Capital Management, Llc. Insider selling has been observed over the past three months.